Showing 3541-3550 of 10618 results for "".
Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma
https://reachmd.com/programs/cme/Photobiomodulation-A-Non-Invasive-Treatment-for-Ocular-Disease-and-Trauma/35945/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, effTeledermatology Enables Earlier Diagnosis of Cutaneous Squamous Cell Carcinoma
https://reachmd.com/programs/clinicians-roundtable/teledermatology-enables-earlier-diagnosis-of-cutaneous-squamous-cell-carcinoma/54695/Understanding the Role of the Alternate Complement Pathway in PNH
https://reachmd.com/programs/project-oncology/understanding-the-role-of-the-alternate-complement-pathway-in-pnh/48875/How does the alternate complement pathway apply in the PNH treatment landscape? Tune in to learn more about its role.Next-Generation Horizons in PNH Therapies
https://reachmd.com/programs/project-oncology/next-generation-horizons-in-pnh-therapies/48873/What can we expect from PNH therapies that are on the horizon? Tune in to learn more.Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
https://reachmd.com/programs/clinicians-roundtable/consensus-and-standards-to-imrpove-continuity-of-care-in-sickle-cell-disease/24061/Unmasking IgG4-Related Disease: Best Practices for Accurate Diagnosis and Optimal Care
https://reachmd.com/programs/living-rheum/unmasking-igg4-related-disease-best-practices-for-accurate-diagnosis-and-optimal-care/32788/IgG4-related disease presents significant diagnostic challenges with diverse symptoms across organ systems. Dr. Matthew Baker, Associate Division Chief in the Division of Immunology and Rheumatology at Stanford University and the Co-Founder and Co-Director of the Stanford Multidisciplinary SarcoidosIn The Pipeline: Phase 1, 2, and 3
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/pipeline-phase-1-2-and-3/29087/This summary provides the latest news on of some of the recent Phase 1, Phase 2, and Phase 3 clinical studies for psoriasis treatments.Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/annual-trends-in-medicare-part-d-prescription-claims-for-guselkumab-20182020/28861/Jachin Wu, MD, FAAD, and colleagues talk about Medicare claims for guselkumabOptimizing Psoriasis Treatment: GUIDE Trial Outcomes on Guselkumab Dosing
https://reachmd.com/programs/dermconsult/optimizing-psoriasis-treatment-guide-trial-outcomes-on-guselkumab-dosing/26385/Dive into the findings from a study that explored whether extending the dosing interval of guselkumab could provide similar efficacy.Closing Gaps in Care for Patients with T2D & CV Disease
https://reachmd.com/programs/diabetes-discourse/closing-gaps-in-care-for-patients-with-t2d-cv-disease/15148/Learn more about obstacles to care for patients with type 2 diabetes and cardiovascular disease from the recent COORDINATE study.